Overview

ENABLING THE ACTIVATION AND ENHANCEMENT OF THE HUMAN IMMUNE SYSTEM WITH SYNTHETIC VECTOR-BASED THERAPEUTICS

Welcome to the DevaCell revolution. We are a transformative biopharmaceutical company focused on the development of high impact, synthetic vector-based therapeutics that offer the potential to revolutionize patient care and improve outcomes for patients across a wide range of therapeutic indications.

While current therapeutic approaches have improved outcomes for some patients, many patients unfortunately do not adequately respond. At DevaCell, we believe we can enable therapies that can treat a significantly larger patient population utilizing the company’s revolutionary ONCoat synthetic vector platform.

DevaCell’s lead product development program is focused on the development of a product pipeline of synthetic, oncolytic virus therapies that can activate and enhance a patient’s own immune response by the repeat administration of a systemically delivered therapeutic, targeting multiple cancer indications. Each product candidate is designed to selectively target, attack and kill cancer cells by the activation and enhancement of the immune system using synthetic vectors engineered to express novel combinations of transgenes that include immunomodulators, checkpoint inhibitors, ligands for T-cell costimulation or coinhibitory receptors.

ENABLING THE ACTIVATION AND ENHANCEMENT OF THE HUMAN IMMUNE SYSTEM WITH SYNTHETIC VECTOR-BASED THERAPEUTICS

Welcome to the DevaCell revolution. We are a transformative biopharmaceutical company focused on the development of high impact, synthetic vector-based therapeutics that offer the potential to revolutionize patient care and improve outcomes for patients across a wide range of therapeutic indications.

While current therapeutic approaches have improved outcomes for some patients, many patients unfortunately do not adequately respond. At DevaCell, we believe we can enable therapies that can treat a significantly larger patient population utilizing the company’s revolutionary ONCoat synthetic vector platform.

DevaCell’s lead product development program is focused on the development of a product pipeline of synthetic, oncolytic virus therapies that can activate and enhance a patient’s own immune response by the repeat administration of a systemically delivered therapeutic, targeting multiple cancer indications. Each product candidate is designed to selectively target, attack and kill cancer cells by the activation and enhancement of the immune system using synthetic vectors engineered to express novel combinations of transgenes that include immunomodulators, checkpoint inhibitors, ligands for T-cell costimulation or coinhibitory receptors.

We must also be clear and state that our mission is both professional and personal. We are all too well aware of the devastating effects serious disease and disorder have on our friends, family and each and every one of us. Recognizing the significant, unmet medical need, DevaCell’s mission is driven by an urgency to discover, develop and bring game changing new therapeutics to patients in need. This mission is with us, each and every day, providing inspiration and motivation to do more and to do more faster in order to transform patient care as quickly as possible. That is our promise and commitment.

OUR TEAM

DevaCell has built an incredible, entrepreneurial team, bringing together visionary leaders with deep expertise in the discovery, development and commercialization of novel, next generation therapeutics. Representing over 100 years of combined experience in the identification of novel product candidates, the advancement of product candidates from the discovery phase to preclinical development, translating research programs to clinical development and ultimately, navigating to FDA approval and commercialization. We recognize that there is so much more to do and welcome your participation and support in this endeavor.